These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 38117332)

  • 1. A systematic review and meta-analysis of the efficacy of ketamine and esketamine on suicidal ideation in treatment-resistant depression.
    Wang YT; Wang XL; Lei L; Guo ZY; Kan FF; Hu D; Gai C; Zhang Y
    Eur J Clin Pharmacol; 2024 Feb; 80(2):287-296. PubMed ID: 38117332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis.
    Seshadri A; Prokop LJ; Singh B
    J Affect Disord; 2024 Jul; 356():379-384. PubMed ID: 38537759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review.
    Siegel AN; Di Vincenzo JD; Brietzke E; Gill H; Rodrigues NB; Lui LMW; Teopiz KM; Ng J; Ho R; McIntyre RS; Rosenblat JD
    J Psychiatr Res; 2021 May; 137():426-436. PubMed ID: 33774537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials.
    Witt K; Potts J; Hubers A; Grunebaum MF; Murrough JW; Loo C; Cipriani A; Hawton K
    Aust N Z J Psychiatry; 2020 Jan; 54(1):29-45. PubMed ID: 31729893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/esketamine.
    Singh B; Vande Voort JL; Pazdernik VK; Frye MA; Kung S
    J Affect Disord; 2024 Apr; 351():534-540. PubMed ID: 38302067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression.
    Gutierrez G; Swainson J; Ravindran N; Lam RW; Giacobbe P; Karthikeyan G; Kowara A; Do A; Baskaran A; Nestor SM; Kang MJY; Biorac A; Vazquez G
    Psychiatry Res; 2024 Oct; 340():116125. PubMed ID: 39128167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".
    Borentain S; Desai P; Fu DJ; Nancy Chen L; Lane R; Mathews M; Canuso CM
    J Psychopharmacol; 2023 Aug; 37(8):836-844. PubMed ID: 36218274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
    Ionescu DF; Bentley KH; Eikermann M; Taylor N; Akeju O; Swee MB; Pavone KJ; Petrie SR; Dording C; Mischoulon D; Alpert JE; Brown EN; Baer L; Nock MK; Fava M; Cusin C
    J Affect Disord; 2019 Jan; 243():516-524. PubMed ID: 30286416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses.
    Lima TM; Visacri MB; Aguiar PM
    Eur J Clin Pharmacol; 2022 Mar; 78(3):311-338. PubMed ID: 34705064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial.
    Zhou Y; Lan X; Wang C; Zhang F; Liu H; Fu L; Li W; Ye Y; Hu Z; Chao Z; Ning Y
    J Am Acad Child Adolesc Psychiatry; 2024 May; 63(5):507-518. PubMed ID: 37414272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esketamine: A Novel Option for Treatment-Resistant Depression.
    Bozymski KM; Crouse EL; Titus-Lay EN; Ott CA; Nofziger JL; Kirkwood CK
    Ann Pharmacother; 2020 Jun; 54(6):567-576. PubMed ID: 31795735
    [No Abstract]   [Full Text] [Related]  

  • 12. Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis.
    Calder CN; Kwan ATH; Teopiz KM; Wong S; Rosenblat JD; Mansur RB; Rhee TG; Ho R; Cao B; McIntyre RS
    J Affect Disord; 2024 Jul; 356():753-762. PubMed ID: 38636712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis.
    Chen CC; Zhou N; Hu N; Feng JG; Wang XB
    Neuropsychiatr Dis Treat; 2023; 19():587-599. PubMed ID: 36942150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of racemic ketamine or esketamine monotherapy for reducing suicidal ideation in uni- or bipolar depression: a systematic review and meta-analysis.
    Li J; Ma L; Sun H; Li M; Cao Y; Peng Y; Xu J
    Eur Arch Psychiatry Clin Neurosci; 2024 Oct; ():. PubMed ID: 39382685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review.
    Ng J; Rosenblat JD; Lui LMW; Teopiz KM; Lee Y; Lipsitz O; Mansur RB; Rodrigues NB; Nasri F; Gill H; Cha DS; Subramaniapillai M; Ho RC; Cao B; McIntyre RS
    J Affect Disord; 2021 Oct; 293():285-294. PubMed ID: 34225208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
    Fu DJ; Ionescu DF; Li X; Lane R; Lim P; Sanacora G; Hough D; Manji H; Drevets WC; Canuso CM
    J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32412700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
    Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Mao WC; Tu PC; Chen LF; Li WC; Chen MH
    Int J Neuropsychopharmacol; 2023 May; 26(5):331-339. PubMed ID: 36966411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
    JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis.
    Jawad MY; Di Vincenzo JD; Ceban F; Jaberi S; Lui LMW; Gillissie ES; Alnafeesi Y; Rosenblat JD; McIntyre RS
    Expert Opin Drug Saf; 2022 Jun; 21(6):841-852. PubMed ID: 35387538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.